LB Pharmaceuticals Inc Common Stock

LBRX · NASDAQ · Healthcare / Biotechnology

43.01USD+0.55 (+1.30%)

Price History

Full chart

Market Stats

Previous Close42.46

Open42.66

Day Range41.03 – 43.43

52-Week Range14.32 – 50.16

Volume330.17K

Market Cap1.20B

P/E (TTM)0.00

Forward P/E0.00

EPS-5.10

Dividend Yield0.00%

50-Day Avg43.28

200-Day Avg30.40

About

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMs. Heather D. Turner Esq., J.D.
Employees49
HeadquartersOne Pennsylvania Plaza, New York, NY, United States, 10119, USA
Websitehttps://lbpharma.us

Leadership

Ms. Heather D. Turner Esq., J.D.CEO & Director · b. 1973
Mr. Gad SofferChief Operating & Business Officer · b. 1977

Financials

Income Statement

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	0
Cost of Revenue	-	-	-	321.00K
Gross Profit	-	-	-	-321.00K
Operating Expense	-	-	-	30.08M
Operating Income	-2.81M	-11.38M	-64.83M	-30.40M
EBITDA	-12.19M	-1.45M	-63.01M	-24.88M
Net Income	-14.35M	-6.28M	-63.10M	-25.20M
R&D	1.35M	7.84M	51.17M	16.74M
Interest Expense	2.15M	4.83M	0	-

Balance Sheet

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	21.49M	45.66M	33.53M	312.93M
Total Liabilities	50.30M	80.13M	128.09M	11.62M
Total Equity	-28.81M	-34.47M	-94.55M	301.31M
Cash	21.40M	14.98M	22.98M	250.17M
Total Debt	24.15M	-	3.70M	3.57M
Net Debt	2.74M	-14.98M	-19.27M	-246.60M

Cash Flow

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-2.73M	-12.09M	-53.05M	-35.21M
Investing Cash Flow	123.00K	-28.01M	23.23M	-39.89M
Financing Cash Flow	22.96M	33.68M	38.31M	302.56M
Capital Expenditure	0	25.00K	769.00K	52.00K
Free Cash Flow	-2.73M	-12.12M	-53.82M	-35.26M
FCF to OCF	100.00%	100.21%	101.45%	100.15%

Earnings

Report Date	Sep 3, 2025	Nov 6, 2025	Mar 26, 2026	May 15, 2026	Aug 11, 2026	Nov 5, 2026
EPS Estimate	0.00	-0.28	-0.32	-0.70	-0.84	-1.63
EPS Actual	-1.44	-0.61	-0.45	-0.67	-1.71	-
Surprise	-	-117.86%	-40.63%	3.61%	-103.57%	-
Timing	-	Pre-market	After-hours	After-hours	Pre-market	-

Key Statistics & Ratios

Market Cap1.20B

Enterprise Value1.05B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book4.14

EPS-5.10

Book Value11.59

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-91.03M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-50.00%

Return on Assets-29.98%

Shares Outstanding32.26M

Shares Float26.46M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Ownership Breakdown

Institutions: 101.48%
Insiders: 0.24%
Retail / Other: 0.00%

Top Institutional Holders

Deep Track Capital, LP
3.35M10.39%
BlackRock Inc
2.47M7.66%
RA Capital Management, LLC
2.21M6.85%
Trails Edge Capital Partners, LP
1.52M4.72%
COMMODORE CAPITAL LP
1.50M4.65%
TCG Crossover Management, LLC
1.45M4.49%
Caligan Partners LP
1.44M4.46%
JPMorgan Chase & Co
1.43M4.43%
Spruce Street Capital LP
1.38M4.27%
Nantahala Capital Management, LLC
1.05M3.26%
Balyasny Asset Management LLC
923.69K2.86%
Vanguard Capital Management, LLC
894.65K2.77%
Alyeska Investment Group, L.P.
863.95K2.68%
Vivo Capital, LLC
800.00K2.48%
Nan Fung Group Holdings Ltd
630.66K1.96%
Logos Global Management LP
585.00K1.81%

Top Fund Holders

Vanguard MStar Total Stk Mkt Idx Invest
684.01K2.12%
JPMorgan Small Cap Growth A
579.84K1.80%
iShares Russell 2000 ETF
573.03K1.78%
BlackRock Health Sciences Opps Inv A
567.63K1.76%